Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374226 | 0.79 | HCAR2 (0.35) | HCAR2SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL127464 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2SMYD3KDM4EALDH1A1HDAC6 | |
| SCHEMBL11393869 | 0.76 | FDPS (0.46) | HCAR2SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL12631200 | 0.75 | ALDH1A1 (0.41) | HCAR2SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL131458 | 0.74 | CDC7 (0.46) | SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL131132 | 0.73 | DYRK1A (0.35) | SMYD3KDM4EALDH1A1 | |
| SCHEMBL741431 | 0.73 | ALDH1A1 (0.40) | HCAR2SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL19224495 | 0.73 | LMNA (0.56) | SMN1; SMN2CYP11B1EGFRKDM4EALDH1A1 | |
| SCHEMBL2470951 | 0.72 | KDM4E (0.33) | HCAR2SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL21199834 | 0.72 | CCNE1 (0.52) | HCAR2SMN1; SMN2CCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | HCAR2 99/4885SMN1; SMN2 4613/4885CYP11B1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.